Navigation Links
Vaccine for Ebola virus

One of the worlds deadliest diseases, caused by the Ebola virus, may finally be preventable thanks to US and Canadian researchers, who have successfully tested several Ebola vaccines in primates and are now looking to adapt them for human use.

Dr Anthony Sanchez, from the Centers for Disease Control & Prevention in Atlanta, Georgia is presenting an overview of Ebola vaccine development today (Monday 31 March 2008) at the Society for General Microbiologys 162nd meeting being held this week at the Edinburgh International Conference Centre.

The biothreat posed by Ebola virus cannot be overlooked. We are seeing more and more naturally occurring human outbreaks of this deadly disease. With worldwide air travel and tourism the virus can now be transported to and from remote regions of the world. And it has huge potential as a possible weapon of bioterrorism, says Dr Sanchez. We desperately need a protective vaccine.

So far, there have been over 1500 cases of Ebola haemorrhagic fever in humans. Illness starts abruptly and symptoms include fever, headache, sore throat, weakness, joint and muscle aches, diarrhoea, vomiting and stomach pain. A rash, red eyes and bleeding may also occur. Ebola haemorrhagic fever can have a mortality rate of around 90% in humans.

Because Ebola virus is so dangerous, producing and testing a vaccine is extremely challenging for the scientists. One significant factor slowing down progress has been that there are only a very limited number of high containment facilities with staff capable and authorised to conduct the research.

Ebola virus is a Biosafety Level 4 threat, along with many other haemorrhagic fever viruses, says Dr Sanchez. As well as the difficulty in getting the right staff and facilities, vaccines for viruses like Ebola, Marburg and Lassa fever have been difficult to produce because simple killed viruses that just trigger an antibody response from the blood are not effective. For these viruses we need to get a cell-mediated response, which involves our bodies producing killer T-cells before immunity is strong enough to prevent or clear an infection.

The researchers have now used several different recombinant DNA techniques, which have allowed them to trigger a cell-mediated response and produce a vaccine that is effective in non-human primates. One of the candidate vaccines is about to be tested on people for the first time, after entering Phase 1 clinical trials in autumn 2006.

Ebola virus infection of humans can be highly lethal but monkeys rarely survive the infection and have been very useful as animal models. Ebola vaccine trials using nonhuman primates have provided unambiguous results and have allowed the development of protective vaccines to progress rapidly, says Dr Sanchez. Successful human trials will mean that we can vaccinate healthcare workers and other key personnel during outbreaks of Ebola haemorrhagic fever, helping us to protect their lives and control the spread of the disease.

The US team hopes that the findings from their studies will provide important insights that will improve or accelerate the future development of vaccines for other haemorrhagic fever viruses like Marburg virus, and agents such as HIV and avian influenza.


Contact: Lucy Goodchild
Society for General Microbiology

Related biology news :

1. Iowa State researchers look for smaller, cheaper, 1-dose vaccines
2. HIV isolate from Kenya provides clues for vaccine design
3. CWRU School of Medicine has evidence vaccine against malaria will reduce disease
4. Penn researchers find monkeys able to fend off AIDS-like symptoms with enhanced HIV vaccine
5. An Alzheimers vaccine?
6. Influenza vaccine causes weaker immune response for children of rural Gabon than in semi-urban areas
7. Flu vaccine in painless skin patches under development at Emory, Georgia Tech with NIH grants
8. New nanoparticle vaccine is more effective but less expensive
9. Study by Pittsburgh researchers identifies possible vaccine target for chlamydia
10. Possible hepatitis C vaccine
11. Ebola virus disarmed by excising a single gene
Post Your Comments:
(Date:11/20/2015)... 20, 2015 NXTD ) ("NXT-ID" ... the growing mobile commerce market and creator of the ... , was recently interviewed on The RedChip Money ... this weekend on Bloomberg Europe , Bloomberg Asia, ... --> NXTD ) ("NXT-ID" or the "Company"), a ...
(Date:11/19/2015)... Nov. 19, 2015  Although some 350 companies are ... by a few companies, according to Kalorama Information. These include ... of the market share of the 6.1 billion-dollar molecular ... World Market for Molecular Diagnostic s .    ... is still controlled by one company and only a ...
(Date:11/18/2015)... New York , November 18, 2015 ... Market Research has published a new market report titled ... Growth, Trends, and Forecast, 2015 - 2021. According to the ... in 2014 and is anticipated to reach US$29.1 bn ... to 2021. North America ...
Breaking Biology News(10 mins):
(Date:11/25/2015)... 26, 2015 --> ... 2016 - 2020 report analyzes that automating biobanking ... quality in long-term samples, minimizing manual errors, improving ... minimizes manual errors such as mislabeling or inaccurate ... it plays a vital role in blood fractionation, ...
(Date:11/25/2015)... 2015  Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) ... CEO of Neurocrine Biosciences, will be presenting at the ... New York . .   ... 5 minutes prior to the presentation to download or ... will be available on the website approximately one hour ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... uBiome, were featured on AngelList early in their initial angel funding process. Now, ... syndicate for individuals looking to make early stage investments in the microbiome space. ...
(Date:11/24/2015)... 24, 2015 /CNW/ - iCo Therapeutics ("iCo" or "the ... results for the quarter ended September 30, 2015. ... dollars and presented under International Financial Reporting Standards ... ," said Andrew Rae , President & ... are not only value enriching for this clinical ...
Breaking Biology Technology: